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ABSTRACT
Objectives: The 2007 National Health Service Cancer Reform Strategy
includes a proposed extension of the UK breast screening program to
women aged 47 to 49 years. The aim of this study is to undertake a
preliminary assessment of this proposal to identify the key factors deter-
mining its cost-effectiveness and to determine whether there is sufﬁcient
uncertainty that requires more thorough analyses.
Methods: An economic model was constructed. For simplicity, the health
impact of screening was estimated by calculating the lives saved through
shifts in prognostic group. A “plausible bounds” approach was used to
derive distributions for model parameters for probabilistic sensitivity
analysis. UK data were used to populate the model.
Results: The cost-effectiveness of the extension is estimated to be £27,400
per quality-adjusted life-year (QALY) with a 29% probability of
cost-effectiveness at a threshold of £20,000 per QALY. The deterministic
estimate of beneﬁt becomes negative if the anxiety due to a false-positive
result is set at 0.028 QALYs. Including a small positive beneﬁt from a
negative screen has a dramatic impact on the cost-effectiveness of screen-
ing. The impact of other factors appears less marked.
Conclusions: Because the vast majority of women aged 47 to 49 years will
test negative when screened for breast cancer and most of those who test
positive will actually be free of the disease, the psychological impacts of
screening are likely to drive cost-effectiveness for this age group. There-
fore, a research priority should be to better understand and quantify these
effects.
Keywords: decision-analytic model, economic evaluation, mammography,
population screening.
Introduction
The UK National Health Service breast cancer screening program
(NHSBSP) was introduced in 1988. Initially targeted at women
aged 50 to 64 years, it was extended to include women aged 65
to 70 years following the recommendations of the 2000 NHS
Cancer Plan [1]. The program involves inviting women to be
screened once every 3 years and has led to a reduction in UK
breast cancer mortality [2]. Following the recommendations of
the 2007 NHS Cancer Reform Strategy [3], further extension of
the NHSBSP is planned in England, including an extra screening
round targeted at women aged 47 to 49 years.
Randomized control trials have demonstrated the ability of
screening by mammography to reduce breast cancer mortality
[4]. Nevertheless, a signiﬁcant period of time has passed since
these trials were conducted. Improvements in breast cancer
screening and treatment prevent the direct application of ﬁndings
from these trials to policy proposals such as the Cancer Reform
Strategy. Furthermore, the age of the population being screened
and the proposed frequency of screening differ from trial proto-
cols. Mathematical modeling can be used to synthesize trial
results, routine data, and resource use information to evaluate
the cost-effectiveness of speciﬁc screening programs [5]. The
Cancer Information and Surveillance Modelling Network
(CISNET) breast cancer screening project represents a state-of-
the-art example of the use of modeling to evaluate the relative
contribution of screening and adjuvant therapy to reducing
breast cancer mortality in the United States between 1975 and
2000 [6]. The CISNET project involved a range of modeling
approaches with different biologic assumptions and illustrated
the challenges involved in modeling the effectiveness of breast
cancer screening, and the level of research time and resources
required to develop such models.
The analysis necessarily becomes even more complex if it is to
address cost-effectiveness as well as efﬁcacy. The direct costs of
screening can be assessed with little difﬁculty. Nevertheless, by
leading to detection at an earlier stage, screening will reduce the
need for more aggressive treatments such as mastectomy. The
resource implications of this are difﬁcult to estimate [7]. A further
complication arises in determining the scope of costs and beneﬁts
to include in the analysis. In particular, assessing the psychological
impact of screening on participants is far from straightforward. If
a woman is told that she has, or may have, breast cancer, it will
clearly cause considerable distress in the short term, although the
longer-term consequences will depend on whether or not the
disease is actually present. This harm will be subjective, personal,
and difﬁcult to measure, which makes its inclusion in any quan-
titative evaluation of the screening program problematic. Never-
theless, the anxiety induced in the short term is likely to be
marked, and any such evaluation would be strengthened greatly
by including it. In younger women, breast cancer prevalence is
lower, and mammography has a lower positive predictive value
[8]. This will increase the impact of anxiety from false positives on
the cost-effectiveness of screening for this age group.
Receiving such a false-positive diagnosis may also inﬂuence a
woman’s decision to attend further screening rounds, although
the impact is not easy to predict. It may lead to a loss of faith in
screening, and hence reduced participation; alternatively, it may
lead to greater awareness of the disease and an increase in com-
pliance. A recent systematic review of this issue found that
compliance among women who had previously received a false-
positive diagnosis, compared with those who had not previously
been screened, was 20% lower in Canada, comparable in
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Europe, and 7% higher in the United States [9]. A study of
women who had received false-positive results in the NHSBSP
found that their compliance rate fell by 2.7% [10].
Objective
As a result of the complexities described above, an exhaustive
evaluation of the proposed screening program extensionwould be
a lengthy exercise. Policymakers may be willing to trade off a
degree of precision for timeliness in a rapid-response analysis. This
initial work would have two goals—to provide a timely order-of-
magnitude estimate of the cost-effectiveness of the proposal and to
determine which factors do and do not have a meaningful impact
on the estimate, to guide the scope of any further analysis or data
collection that may be considered necessary. Our objective was to
perform this rapid-response evaluation for the proposed screening
round aimed at women aged 47 to 49 years.
Methods
The length of time needed to carry out model-based evaluations
of breast cancer screening is driven by the difﬁculties of devel-
oping and populating complex representations of breast cancer
natural history and the impact of screen detection on prognostic
factors and subsequent outcomes [11]. Our aim was to develop a
model structure that reduced, where practicable, the number of
parameters and biomedical assumptions required. To ensure that
the model was populated in a timely fashion and that the degree
of uncertainty was accurately reﬂected, an approach was adopted
that we describe as a “plausible bounds” method. This method
can be used in situations when data that directly inform a param-
eter value are not readily available (in this case, because data
are not available speciﬁcally for the age groups at which the
intervention is targeted). If data can be identiﬁed which, for
well-grounded clinical reasons, give an underestimate of the
parameter, this places a lower limit on the value needed. If a
second data set can be identiﬁed that provides an overestimate,
then an upper limit can be deﬁned, giving a range that is highly
likely to contain the true value. Plausible bounds for the screen-
ing model were represented as distributions on the parameters to
inform probabilistic sensitivity analysis (PSA). Data that reﬂected
the UK context of the decision were preferred. This led us to rely
on data from the existing screening program, supplemented with
data from a UK trial of screening in women aged 40 to 49 years
[12], for the bulk of information used.
Model Structure
The model (Fig. 1) simulates the experience of a hypothetical
cohort of 10,000 women aged 47 to 49 years attending a single
breast cancer screening appointment. Initially, the number of
women who are referred for further investigation is estimated.
From this group, a proportion of women receive diagnoses of
breast cancer. Both the initial cost of screening and the costs of
further investigation to identify those with breast cancer are
included in the model. For those who have breast cancer, disease
severity is classiﬁed according to the Nottingham Prognostic
Index (NPI) prognostic groups—ductal carcinoma in situ (DCIS),
excellent, good, moderate, and poor [13]. The model estimates
the proportion of screen-detected cases in each of these groups.
As a comparator, it also estimates the proportions that would be
observed if the screening round under evaluation had not taken
place. Using data on the treatment costs and 10-year survival (a
proxy for cure) for each group, the model estimates the impact of
the screening program on treatment costs and mortality for the
cohort. A basic model of the impact of screening on mortality is
used, which assumes that all those who are saved through screen
detection (i.e., the difference in mortality resulting from
improved prognosis, multiplied by the size of the cohort) would
otherwise have died 5 years after the date of screening.
The model translates improved mortality into disease-free
quality-adjusted life-years (QALYs) gained, using data on age-
adjusted quality of life [14]. This allows a full cost-utility analysis
to be carried out. Where appropriate, parameters used in the
model are speciﬁed as stochastic variables. This allows PSA to be
performed via Monte Carlo simulation, and a cost-effectiveness
acceptability curve to be produced, for a reference case where the
impact of screening was limited to improved survival, direct costs
of screening, and changes in treatment cost. There were addi-
tional factors for which the uncertainty could not be quantiﬁed
for inclusion in the PSA. These were the impact of false-positive
results on short-term anxiety and on compliance with future
screening rounds, the reassurance arising from a negative screen
and the impact of technological improvements to mammography.
Separate one-way sensitivity analyses were carried out for these
factors. These analyses represented psychological impacts in
QALY terms, because a common yardstick is required to
combine mortality and morbidity, and the National Institute for
Health and Clinical Excellence (NICE) methods guide recom-
mends the use of the QALY for this purpose [15].
Derivation of Model Parameters
To estimate the number of cancers detected by screening, the
model samples the number of positive results in the cohort and
combines this with an estimate of the percentage of women
testing positive that would actually have breast cancer. Data from
the UK age trial and the 2006/2007 NHSBSP (Table 1) were used
to construct sampling distributions for these parameters for the
40- to 49-year cohort. These data do not provide direct evidence
of the required parameters for the relevant cohort, but it allows
the construction of a plausible range from which to derive sam-
pling distributions. The UK age trial provides randomized
control trial (gold standard) evidence. Nevertheless the age group
of interest is older than that reported in the trial and is likely to
include signiﬁcantly more menopausal women. Because mam-
mography is known to have a lower positive predictive value in
younger women [8], the trial results can be seen as a lower bound
for the model parameters given in Table 2. Conversely, the
NHSBSP provides data from an older cohort, which will there-
fore have a higher percentage of menopausal women than the age
group of interest, thus providing an upper bound. Combining
upper and lower bounds creates sampling distributions for these
model parameters, if it is assumed they represent a 95% conﬁ-
dence interval from a normal distribution. These sampling dis-
tributions are given in Table 2.
The model assumes that all referrals will undergo either a
further mammography or an ultrasound and uses the average
cost of the two procedures. It also assumes, based on practice in
the current screening program, that all patients who ultimately
receive diagnoses of breast cancer receive a biopsy, and 2.4% of
those who are referred but subsequently found to be disease-free
will also undergo this procedure (in the 2006/2007 screening
round, there were 69,000 false positives, of whom 1700 [31%]
underwent a biopsy) [16]. The vast majority (96%) of these were
core biopsies. The costs used are given in Table 3. All costs were
obtained from NHS Reference Costs 2005/2006 and uplifted to
2006/2007 prices using standard indices [17].
To predict the impact of screening on costs and outcomes, the
model predicts the proportions of screen-detected cancers in each
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NPI group and compares this with the proportions for cancers
presenting symptomatically. The source data for this are taken
from the UK age trial, in combination with analysis from an
economic evaluation [7] of the impact of the NHSBSP on treat-
ment costs (Table 4). The proportion of cancers in each NPI
group was used to calculate a weighted average treatment cost
and survival probability for intervention and control arms of the
age trial. The difference between these averages, multiplied by the
number of screen-detected cancers, gives the deterministic esti-
mate of the impact of screening the cohort on lives saved and
change in treatment costs. Lives saved were translated into life-
years gained using standard mortality tables [18] and converted
into QALYs using established tariffs for health-related quality of
life by age [14]. To avoid lead-time bias, the time of death from
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Figure 1 Model structure and information
requirements.
Table 1 Source data for modeling test outcomes
Source
Number
screened Referrals
Cancers
detected
Referral
rate
Positive
predictive value
NHSBSP 2006/2007 ﬁrst attendees aged 50–52 201,627 17,400 1,515 8.63% 8.71%
UK age trial—ﬁrst attendees aged 40–41 35,846 1,655 37 4.58% 2.2%
NHSBSP, National Health Service breast cancer screening program.
Table 2 Sampling distributions for screening outcome parameters
Parameter
Lower
bound
Upper
bound Mean
Standard
error
Referral rate 4.58% 8.63% 6.6% 1.0%
PPV 2.20% 8.71% 5.5% 1.7%
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breast cancer was assumed to be the same irrespective of screen-
ing history, rather than calculating survival from the point of
detection. All costs and beneﬁts were discounted at 3.5%, as
recommended by the UK NICE [15].
The intervention arm of the UK age trial will not necessarily
give the correct prognostic proﬁle of the cancers that would be
detected by the proposed screening round. The population is
younger on average, and the intervention arm includes interval
cancers and nonattenders. These factors will lead to the stage
shift from screen detection being underestimated. At the same
time, using the prognostic proﬁle of screen-detected cancers will
lead to an overestimate of the beneﬁts of screening due to length
bias—the fact that less aggressive cancers will be over-
represented in a screen-detected group of cancers. Furthermore,
the estimate does not take into account the fact that some of the
cancers detected in the proposed screen may have been picked up
in the ﬁrst screen of the current screening program. In a UK
context of triennial screening, this omission is unlikely to be
material because most cancers will have either presented within 3
years or have progressed markedly. Nevertheless, it will add to
the degree of overestimation of the beneﬁts of screening.
To represent the additional uncertainty, we again applied the
plausible bounds approach. Table 4 gives the NPI proﬁle for
cancers detected in the current UK screening program and
presents a calculation of the weighted average survival and
treatment cost for this group. Because this represents an older
population, who will have proportionately fewer aggressive
tumors, this group will have a more favorable prognostic proﬁle
than the cancers detected in the 47- to 49-year age group. It was
therefore used to set the upper bound for the improvement in
survival and treatment costs saved due to screen detection. Zero
is a natural lower bound for the survival impact and treatment
cost savings due to screen detection. Therefore, a log-normal
distribution was used to represent the uncertainty around these
parameters in the PSA, with a mean given by the difference in the
arms of the UK age trial (4.6%, £480) and a 97.5 percentile given
by the difference between the age trial control arm and the UK
NHSBSP (12.7%, £2535). Because both survival and treatment
cost depend on stage shift, the two distributions were assumed to
be perfectly correlated.
Results
Using point estimates for all parameters, it was estimated for the
base-case that 36 cancers would be detected per 10,000 women
screened. Table 4 suggests that the point estimate for the absolute
improvement in survival from screen detection is 4.6% (80.0%
minus 75.6%), giving a total of 1.66 (36 ¥ 4.6%) lives saved per
10,000 women screened. Using UK all-cause mortality data and
age-adjusted QALY tariffs, as described above, this translated
into a gain of 17.5 QALYs. Screening costs for the cohort were
£420,000. The cost of diagnosis for positive results would be
£70,000, and screening would lead to a saving in treatment costs
of £17,000 (£480 per screen-detected cancer, calculated from the
difference in treatment costs for the trial control and intervention
arms in Table 4), giving a net cost of screening of £473,000 per
10,000 screened and an incremental cost-effectiveness ratio
(ICER) of £27,400. Figure 2 presents the results of the PSA. The
base-case PSA suggests that there is a moderate possibility that
the intervention is cost-effective for the 47- to 49-year cohort. At
a willingness-to-pay threshold of £20,000 per QALY, there is an
estimated 29% probability that the additional screening round is
cost-effective, rising to 52% if the threshold is set to £30,000 per
QALY gained. The probabilistic mean was £23,700 per QALY
gained.
Table 3 National Health Service reference costs for activities involved
in screening and subsequent diagnosis
Activity
2005/2006
cost (£)
2006/2007 cost
(2005/2006 + 4.6%) (£)
Initial two-view mammography 40 42
Further mammography 67 70
Ultrasound examination 74 78
Biopsy—open 241 253
Biopsy—core 117 122
Table 4 Data on prevalence and outcomes by prognostic group [26]
Prognosis
10-year
survival
Treatment costs
£2006/2007 [7]
UK age trial—
intervention arm
UK age trial—
control arm
UK NHSBSP
2006/2007
No. (%) No. (%) No. (%)
DCIS 100 7,106 69 14.7% 54 6.9% 3185 21.3%
Excellent 98 8,280 31 6.7% 28 3.6% 2628 17.3%
Good 90 9,392 84 17.9% 101 13.0% 4213 28.3%
Moderate 79 10,481 206 43.9% 422 54.2% 4175 27.6%
Poor 47 12,441 79 16.8% 173 22.2% 778 5.5%
Weighted average:
survival
80.0% 75.4% 88.1%
Weighted average:
treatment cost
£9972 £10,452 £7917
NHSBSP, National Health Service breast cancer screening program; DCIS, ductal carcinoma in situ.
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Several one-way sensitivity analyses were undertaken on
parameters where plausible bounds could not be established.
First, the model assumes that survival from screen detection for
cancers that would prove fatal if not screen-detected is 5 years.
Extending this by 2 years increases the ICER to £30,100 per
QALY gained. This suggests that varying the estimated mean
survival time for a fatal cancer does not have a dramatic impact
on the cost-effectiveness of screening this cohort.
The deterministic base-case was then repeated adding a dis-
utility, in terms of a QALY loss, reﬂecting the short-term anxiety
of a false-positive screen. Table 5 shows the impact on cost-
effectiveness of assigning a range of values to this disutility. Even
if the anxiety caused by the false-positive result is assumed to be
low, the impact is marked. At 0.002 QALYs per false-positive
result, the deterministic estimate of cost-effective rises to £30,000
per QALY. Beyond 0.028 QALYs per false-positive result, the
expected impact of screening on the health of the cohort is
negative and the intervention is not cost-effective at any thresh-
old. A similar sensitivity analysis within the probabilistic model
was performed. Figure 3 shows the impact of increasing values
for short-term anxiety on the probability that the intervention is
cost-effective at the thresholds commonly used by NICE in the
UK. Even if quite low values are used, this parameter once more
has a noticeable impact on the strength of the model’s conclu-
sions. At 0.03 QALYs per person, the probability that the inter-
vention is cost-effective falls to 2% at a threshold of £20,000 per
QALY, and 3% at a threshold of £30,000 per QALY.
There may be positive, as well as negative, psychological
consequences from being screened. A recent study of attitudes to
mammography in women aged more than 70 years found that
some valued the reassurance that a negative result gave them
[19], and there is no reason to suppose this would be different for
other age groups. Figure 4 illustrates the degree to which reas-
surance can offset the anxiety from false-positive diagnoses, by
illustrating the combined values at which the deterministic esti-
mate of incremental cost-effectiveness is £30,000 per QALY
gained. It suggests that even if the individual beneﬁt (in QALY
terms) of this reassurance is low, the cumulative impact on cost-
effectiveness is dramatic.
False-positive results may also have an impact on participa-
tion in subsequent screening rounds. The inﬂuence of this factor
on the overall incremental cost-effectiveness of the additional
screening round will depend on the direction and degree of the
change in compliance, and the cost-effectiveness of the screens
missed. Therefore, substantial data collection and analysis is
required to quantify this inﬂuence. To assess whether such an
effect is justiﬁed, a simple estimate of its size was determined. It
was assumed that the total costs per attendee of each screening
round are likely to be similar to those in the proposed interven-
tion, which the model suggests are approximately £45. If the
existing program is assumed to be moderately cost-effective at
around £15,000 per QALY gained, this would imply a beneﬁt of
0.003 QALYs per participant. It was assumed that compliance
would either be complete or nil, so that all those who comply
with the main program attend seven screening rounds. Discount-
ing at 3.5%, this gave net present costs and beneﬁts of attending
the NHSBSP of £208 and 0.014 QALYs. These were assumed to
be the costs and beneﬁts lost per person choosing not to attend
the existing program. Applying this approximation to a one-way
sensitivity analysis of our base-case, it was found that a 40%
reduction in participation was required in the false-positive
group to raise the ICER to £30,000 per QALY gained, and that
an increase of a similar magnitude would reduce the ICER to
£25,000 per QALY gained. Therefore, even substantial changes
in participation have a modest impact on cost-effectiveness.
Technological change can affect the performance, and there-
fore the cost-effectiveness, of a screening test. It has been dem-
onstrated that digital mammography has signiﬁcantly greater
sensitivity (up to 40% relative improvement) than ﬁlm-based
mammography in the less than 50s [20]. The model can be used
to explore the likely implications of improved technology on the
cost-effectiveness of the proposed intervention using threshold
analysis. Assuming an ability to detect 40% more cases of breast
cancer in the model cohort (50 rather than 36 cases per 10,000
screened) improves the QALYs gained through screening from
17.5 to 24.2 per 10,000 screened. Offsetting this gain will be an
increase in the costs of the test itself. This has been assumed to be
Table 5 Impact of short-term anxiety on the deterministic estimate of
cost-effectiveness
Anxiety due to false-positive
result (QALYs)
0 0.01 0.02 0.03
Incremental cost-effectiveness
ratio (£)
27,000 43,000 96,000 Dominated
QALY, quality-adjusted life-year.
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£42 for the standard test. To restore the cost-effectiveness ratio
found in the base-case, the cost of digital mammography would
need to be at most 45% higher (£61). Beyond £69, the overall
cost-effectiveness of the extra screening round exceeds £30,000
per QALY gained, the upper range of commonly quoted
willingness-to-pay thresholds. This is only an exploratory analy-
sis, but it does suggest that even a substantial improvement in test
performance would be outweighed by fairly modest increases in
cost.
Discussion
Our aim in this preappraisal was to assist decision-makers in two
ways. First, we aimed to assess the need for a detailed analysis of
the extension to the UK breast screening program proposed by
the Cancer Reform Strategy by exploring how likely it was that
it would be cost-effective compared with the status quo. Second,
and perhaps more importantly, it was our aim to investigate the
importance of factors that are cumbersome to evaluate and
include in the decision analysis, to determine whether their
impact on the conclusions made such an effort worthwhile. We
acknowledge that our analysis has involved considerable simpli-
ﬁcation and approximation. Nevertheless, based on our use of
the plausible bounds approach and data that are both recent and
directly relevant to the decision being evaluated, we believe that
our results are of the correct order of magnitude. Our estimate is
not markedly different to results from assessments of the cost-
effectiveness of screening programs targeting the 40- to 49-year
age group [21–23].
Our aims, described above, drove our approach to represent-
ing uncertainty in the analysis. The “plausible bounds” approach
we have adopted was in response to the gap between the infor-
mation given by the available data and the information needed to
populate the model. This is similar to the issue of “external
validity” encountered in attempting to base clinical and policy
decisions on trials whose circumstances differ from the decision
context. If this additional source of uncertainty is ignored, this
will lead to PSA that underestimates the true degree of uncer-
tainty facing the decision-maker.
Our approach to this issue was to identify data that gave
biased estimates in a direction that could be determined a priori,
based on established clinical knowledge. For example, it is
known that both the incidence of breast cancer and the sensitivity
of mammography are higher in postmenopausal women [8]. It
follows that the cancer detection rate in the current screening
program will be higher than that in a screened cohort of women
aged 47 to 49 years. This process allowed us to include the
uncertainty implied by the gap between the available data and
the parameters in the models and to represent a priori knowledge
quantitatively to avoid overstating the uncertainty in the avail-
able evidence base. If every effort is made to conﬁrm with
decision-makers and clinical experts that appropriate data have
been selected to deﬁne the bounds, this process is an efﬁcient way
to capture uncertainty in a “rapid response” analysis of the type
we have performed.
We have used the plausible bounds approach to capture
uncertainty around model parameters wherever possible. The
key exception was the QALY impact of the psychological conse-
quences of the screening round. Although there is considerable
literature on the potential psychological harm of false-positive
mammographies, we are not aware of any attempts to quantify
the impact of such harm for inclusion in analysis of the cost-
effectiveness. We are also unaware of any quantitative analysis in
the literature of a possible psychological beneﬁt to those who
receive a true negative diagnosis, despite reassurance being men-
tioned as an important beneﬁt of screening by some women [19].
Therefore, we undertook one-way sensitivity analyses to identify
thresholds at which these effects had a marked impact. This
analysis suggests that even at modest levels, psychological effects
may drive estimates of the cost-effectiveness of screening. For
false-positive anxiety, a value of 0.01 QALYs would reduce the
probability that the extension is cost-effective to 25%. If the false
positive only leads to distress until the correct result is provided,
then this implies the distress is equivalent to a reduction from full
health of 0.1 QALYs (assuming a delay of around 5 weeks). If,
however, a false-positive result has long-term consequences for
mental well-being in a signiﬁcant proportion of cases, then
the short-term impact need not be as severe. A priority for further
research should be the quantiﬁcation of these effects to support
decision-making, assessing their magnitude and duration.
The psychological consequences described above have not
explicitly been included in decisions to implement the existing
screening program. It might therefore be argued that it would be
inconsistent to consider these effects in the younger population
alone. We would argue that anxiety from false positives will be a
signiﬁcantly less important issue in the current screening
program, particularly in later rounds. This is because mammog-
raphy is more deﬁnitive in postmenopausal women [24]. The age
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of menopause is approximately normally distributed, with mean
51 years and ranging from 40 to 58 years [25]. The cohort
beneﬁting from the proposed extension will therefore have a
higher percentage of premenopausal women. This will lead to a
higher false-positive rate, which is supported by the data—the
false-positive rate was 97.8% in the UK age trial (see Table 1),
but only 84% for the current screening program [16]. Even if
the psychological impact of screening in the current screening
program was thought to be comparable with the proposed exten-
sion, we would still argue that it would be inappropriate to
ignore such a signiﬁcant consequence of the policy solely because
previous decisions did not explicitly take it into account. If
short-term anxiety is found to have a key impact on the cost-
effectiveness of screening, this would suggest that the current
lower age limit is too low. Nevertheless, this is a choice for
decision-makers; our aim is merely to illustrate the strong impact
these factors have if they are included in estimates of the cost-
effectiveness of the proposed extension to the screening program.
Our estimate of the cost impact of screening includes a com-
ponent for changes in treatment. Admittedly, ours is an approxi-
mate estimate of this impact, although the plausible bounds
approach allows us to represent uncertainty around the estimate.
This is a challenging cost to estimate, because the impact of
screen detection on treatment pathways is complex. Our model
suggests that, in this case, this effort may not be worthwhile in
assessing the cost-effectiveness of screening, because it is unlikely
to be important relative to the costs of screening itself.
Conclusions
Because the vast majority of women aged 47 to 49 years will test
negative when screened for breast cancer and most of those who
test positive will actually be free of the disease, the psychological
impacts of screening are likely to drive cost-effectiveness for this
age group. Therefore, a research priority should be to better
understand and quantify these effects. Detailed analysis of the
survival beneﬁts of screening will only be necessary for policy-
making if decision-makers consider the psychological effects to
be irrelevant, or research reveals that they are short-term and
minor. In that case, changes in treatment costs and subsequent
participation resulting from the additional screening round will
not materially affect its cost-effectiveness, and further investiga-
tion can be simpliﬁed by their exclusion.
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